<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791089</url>
  </required_header>
  <id_info>
    <org_study_id>LVZ111900</org_study_id>
    <nct_id>NCT00791089</nct_id>
  </id_info>
  <brief_title>Effects of Fish Oil on Post Ablation Arrhythmias</brief_title>
  <official_title>Effect of Omega-3 Fatty Acids on Short and Long-Term Maintenance of Sinus Rhythm After Radiofrequency Catheter Ablation for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if peri-operative treatment with omega-3 fatty acids is associated with a
      decrease in the incidence of early recurrences of atrial arrhythmias (within 30 days) and an
      improvement in probability of long-term maintenance of sinus rhythm after radiofrequency
      catheter ablation for Atrial Fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AF is the most prevalent arrhythmia, affecting &gt;2 million Americans. Antiarrhythmic drug
      therapy often is ineffective to eliminate recurrent episodes of AF. In recent years
      radiofrequency catheter ablation has emerged as a highly effective treatment strategy in
      patients with paroxysmal and chronic AF.6, 7 However, AF may recur within days to weeks after
      a successful ablation procedure in up to 50% of the patients, probably because of an
      inflammatory response to thermal injury caused by radiofrequency energy application. These
      early recurrences of AF after ablation do not necessarily predict long-term clinical outcome
      and 30-50% of patients who develop early recurrences ultimately remain in sinus rhythm
      without the need for additional ablation.8 However, early recurrences of AF may be associated
      with significant morbidity due to troubling symptoms of rapid ventricular rates, multiple
      hospital visits and cardioversions, need for antiarrhythmic drug therapy and prolongation in
      duration of anticoagulant therapy. It is also possible that if early recurrences of AF after
      ablation can be avoided, the probability of remaining in sinus rhythm during long-term
      follow-up may be higher, as maintenance of sinus rhythm early-on may facilitate reverse left
      atrial remodeling. A similar phenomenon may occur in post-operative AF, that develops in ~30%
      of patients who undergo cardiac surgery. Post-operative AF is often transient and usually
      resolves within 3 months after the surgery. Perioperative treatment with omega-3 fatty acids
      has been reported to decrease the incidence of postoperative AF after coronary artery by-pass
      surgery.4 Because the pathogenetic factors that play a role in postoperative AF and early
      recurrences of AF after radiofrequency catheter ablation may be similar, it is plausible that
      treatment with omega-3 fatty acids before and after ablation will be associated with a
      reduction in the incidence of early recurrences of AF.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to secure funding and long term follow up
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Normal Sinus Rhythm (Freedom From Atrial Arrhythmias)</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from atrial arrhythmias at 6 months will be defined as absence of any atrial arrhythmias with or without antiarrhythmic drug (AAD) therapy as shown in the two lines</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Fish Oil, Ablation, Sinus Rhythm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, Ablation, sinus rhythm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOVAZA Omega 3-acid ethyl esters</intervention_name>
    <description>Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.</description>
    <arm_group_label>Fish Oil, Ablation, Sinus Rhythm</arm_group_label>
    <other_name>Fish Oil</other_name>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOVAZA</intervention_name>
    <description>(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
    <arm_group_label>Fish Oil, Ablation, Sinus Rhythm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Control group will receive placebo before &amp; after ablation.</description>
    <arm_group_label>placebo, Ablation, sinus rhythm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and &lt; 70 years old

          -  Left atrial size &lt;55 mm

        Exclusion Criteria:

          -  Inability or unwillingness to provide informed consent

          -  Current therapy with omega-3 fatty acids

          -  Current therapy with a statin

          -  Active liver disease

          -  Significant comorbidity such as end-stage renal disease or cirrhosis

          -  Valvular prosthesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakan Oral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Cardiovascular Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <results_first_submitted>March 24, 2017</results_first_submitted>
  <results_first_submitted_qc>March 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Hakan Oral</investigator_full_name>
    <investigator_title>Cardiology EP Director</investigator_title>
  </responsible_party>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All of the 12 participants were assigned to an intervention, but none completed all aspects of the study, because of study termination due to funding withdrawal. Still, basic baseline and outcome measure data was available for 11 of the 12, as noted below.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil, Ablation, Sinus Rhythm</title>
          <description>Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
LOVAZA Omega 3-acid ethyl esters: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
LOVAZA: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Ablation, Sinus Rhythm</title>
          <description>Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
placebo: Control group will receive placebo before &amp; after ablation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Began Actually Taking Fish Oil or Placeb</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Six-month Data Collected</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis is provided for all persons who actually began their assignment.</population>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil, Ablation</title>
          <description>Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
LOVAZA Omega 3-acid ethyl esters: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
LOVAZA: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Ablation, Sinus Rhythm</title>
          <description>Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
placebo: Control group will receive placebo before &amp; after ablation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One age for one participant randomized to this arm is unavailable. This participant actually never began placebo.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="43" upper_limit="64"/>
                    <measurement group_id="B2" value="48.8" lower_limit="26" upper_limit="65"/>
                    <measurement group_id="B3" value="52.7" lower_limit="26" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Normal Sinus Rhythm (Freedom From Atrial Arrhythmias)</title>
        <description>Freedom from atrial arrhythmias at 6 months will be defined as absence of any atrial arrhythmias with or without antiarrhythmic drug (AAD) therapy as shown in the two lines</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil, Ablation</title>
            <description>Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
LOVAZA Omega 3-acid ethyl esters: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
LOVAZA: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Ablation</title>
            <description>Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
placebo: Control group will receive placebo before &amp; after ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normal Sinus Rhythm (Freedom From Atrial Arrhythmias)</title>
          <description>Freedom from atrial arrhythmias at 6 months will be defined as absence of any atrial arrhythmias with or without antiarrhythmic drug (AAD) therapy as shown in the two lines</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FREEDOM FROM ATRIAL ARRHYTHMIAS WITHOUT AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FREEDOM FROM ATRIAL ARRHYTHMIAS WITH AAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil, Ablation</title>
          <description>Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
LOVAZA Omega 3-acid ethyl esters: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
LOVAZA: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.</description>
        </group>
        <group group_id="E2">
          <title>Placebo, Ablation</title>
          <description>Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
placebo: Control group will receive placebo before &amp; after ablation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac Tamponnade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Painful vericose veins</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spot on Face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fluid gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Study was terminated before subject enrollment completion, due to financial concerns and loss of major support from the 21-day cardiac monitoring device. So small sample size means data should be interpreted with great caution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hakan Oral</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734 936-6868</phone>
      <email>oralh@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

